Zeo ScientifiX Stock Price, News & Analysis

Zeo ScientifiX, Inc. (OTCQB:ZEOX) is a clinical-stage biopharmaceutical company specializing in the development of innovative biological therapeutics for chronic diseases. Founded in 2011 and headquartered at Nova Southeastern University's Collaborative Center for Research in Davie, Florida, Zeo ScientifiX was formerly known as Organicell Regenerative Medicine, Inc. The company underwent a rebranding in March 2024 to better reflect its mission and cutting-edge research initiatives.

The core of Zeo ScientifiX's business lies in the development of proprietary products derived from perinatal, allogenic, and autologous sources. These products are meticulously manufactured in an FDA-registered, cGMP-compliant laboratory to retain essential bioactive components such as exosomes, hyaluronic acid, and proteins without the addition of any other substances or diluents.

Notably, Zeo ScientifiX has made significant strides in its clinical research programs. Their flagship product, Zofin™, which contains high concentrations of nanoparticles including exosomes, growth factors, and bio-active proteins, has shown promising safety outcomes across multiple Phase 1 studies, including trials for knee osteoarthritis and moderate-to-severe COVID-19. With no reported therapy-related safety events, the company is positioned to advance to larger Phase 2 studies in 2024.

In recent developments, Zeo ScientifiX announced a 1-for-200 reverse split of its common stock, aimed at improving marketability and attracting institutional investors. The company also welcomed Howard L. Golub, MD, PhD, as its new Executive Vice President and Chief Science Officer, bringing a wealth of experience in clinical research and drug development.

Zeo ScientifiX's commitment to pioneering research is further strengthened by its strategic partnerships, including a collaboration with Regenerative Care Network to explore the therapeutic benefits of Zofin™ for heart failure patients. The company continues to enhance its leadership team and expand its research capabilities, aiming to redefine the standard of care for chronic diseases through innovative biologic therapies.

For more information, please visit https://zeoscientifix.com/.